Collecting and analyzing lung tissue samples from patients with non-small cell lung cancer
Molecular Fingerprinting of Lung Cancer
This study is trying to see if analyzing lung tissue samples from patients with non-small cell lung cancer can help predict how their tumors will behave and how well they might do after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | Vanderbilt-Ingram Cancer Center Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 3 sites (Nashville, Tennessee and 2 other locations) |
| Trial ID | NCT00897117 on ClinicalTrials.gov |
What this trial studies
This research focuses on collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer. The study aims to develop statistical and computational methods to model the relationships between protein and RNA expression data and clinical outcomes. By examining tissue samples, researchers will identify molecular features that may predict tumor behavior and correlate these findings with clinical data, such as recurrence and survival rates. The study involves multiple centers and utilizes advanced techniques like gene expression analysis and microarray analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with resectable stage I or II non-small cell lung cancer who are undergoing surgical resection.
Not a fit: Patients who have received chemotherapy or radiotherapy prior to surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of lung cancer biology and the development of new biomarkers for better patient outcomes.
How similar studies have performed: Other studies have shown success in analyzing tumor tissue samples to identify biomarkers, making this approach promising but not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Diagnosis of non-small cell lung cancer * Clinical stage I and II disease * Resectable disease and complete surgical resection planned * Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network * Tumor specimen samples must be available at resection Exclusion criteria * Chemotherapy before surgery * Radiotherapy before surgery
Where this trial is running
Nashville, Tennessee and 2 other locations
- Dan Rudy Cancer Center at Saint Thomas Hospital — Nashville, Tennessee, United States (Completed)
- Veterans Affairs Medical Center - Nashville — Nashville, Tennessee, United States (Suspended)
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States (Recruiting)
Study contacts
- Principal investigator: Eric Grogan, MD — Vanderbilt Medical Center
- Study coordinator: VICC Clinical Trials Information Program
- Email: cip@vumc.org
- Phone: 800-811-8480
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.